false000184022900018402292024-05-132024-05-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2024

 

 

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40908

82-2142067

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

149 Fifth Avenue

Suite 500

 

New York, New York

 

10010

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 994-8250

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

INKT

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.01 Entry into a Material Definitive Agreement.

The disclosure set forth below under Item 3.02 is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

On May 13, 2024, MiNK Therapeutics, Inc. (the “Company”) entered into a Stock Purchase Agreement with a certain investor (the “Purchaser”), as identified on Exhibit A to the Stock Purchase Agreement, pursuant to which the Company issued and sold an aggregate of 4,640,000 shares of Common Stock (the “Common Shares”), at a purchase price of $1.25 per share, a 25% premium to the 30-day volume-weighted average stock price. The Company received net proceeds of approximately $5.8, after offering expenses. The transaction closed on May 14, 2024.

 

The Stock Purchase Agreement requires the Company to register the resale of the Common Shares. The Company is generally required to prepare and file a registration statement with the Securities and Exchange Commission (the “Commission”) on or before August 15, 2024, and to use commercially reasonable efforts to have the registration statement declared effective within 30 days if there is no review by the Commission, and within 90 days following receipt of written comments in the event of such review. In addition, the Purchaser has agreed not sell of any of the Common Stock prior to November 9, 2024 and to vote all of the shares of Common Stock that it then owns in accordance with the recommendation of the Company’s board of directors on all matters presented to the Company’s stockholders through May 14, 2025.

 

The Common Shares were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The Common Shares may not be offered or sold in the United States without an effective registration statement or pursuant to an exemption from applicable registration requirements. This Current Report on Form 8-K is not an offer to sell or the solicitation of an offer to buy the Securities.

 

The above description of the material terms of the offering is qualified in its entirety by reference to the Stock Purchase Agreement, a copy of which will be filed, with confidential terms redacted, as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

May 16, 2024

By:

/s/ Jennifer Buell

 

 

 

Jennifer Buell, CEO

 

v3.24.1.1.u2
Document And Entity Information
May 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 13, 2024
Entity Registrant Name MiNK Therapeutics, Inc.
Entity Central Index Key 0001840229
Entity Emerging Growth Company true
Entity File Number 001-40908
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-2142067
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8250
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol INKT
Security Exchange Name NASDAQ
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more MiNK Therapeutics Charts.
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more MiNK Therapeutics Charts.